Form 4: Alzamend Neuro Director Sells Over $184K in Stock

Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc., reported selling 79,628 shares of common stock for approximately $184,161 across three transactions in late September 2025.

Summary

• Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc. (ALZN), reported multiple sales of common stock.
• A total of 79,628 shares were sold across three transactions between September 26, 2025, and September 30, 2025.
• The sales were executed at prices ranging from $2.309 to $2.3334 per share.
• The total proceeds from these sales amounted to approximately $184,161.
• Following these transactions, Mr. Ault's beneficial ownership includes 31,626 shares indirectly through Ault Lending, LLC, 1,843 shares directly, 11,068 shares indirectly through Ault Life Sciences, Inc., and 61 shares indirectly through Ault Life Sciences Fund, LLC, totaling 44,598 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director and 10% owner, which typically signals a lack of confidence or a belief that the stock is overvalued. This can lead to negative market perception.

Negatives

• A Director and 10% Owner selling a significant number of shares can be perceived negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects.
• The sale of 79,628 shares represents a substantial reduction in the reporting person's direct and indirect holdings related to the Ault Lending, LLC entity.

Risks

• Insider selling by a director and significant shareholder may lead to negative investor sentiment and potential downward pressure on the stock price.
• A reduction in insider ownership could be interpreted as a signal of potential future challenges or a belief that the stock is fully valued or overvalued.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider selling, particularly by a director and significant shareholder, is often closely watched by investors as it can provide insights into management's perception of the company's valuation or future prospects. In the biotechnology or pharmaceutical industry, such sales might be scrutinized for any implications regarding clinical trial progress, regulatory approvals, or commercialization timelines, though this filing does not provide such context.

Related Party Transactions

• Milton C. Ault III's indirect beneficial ownership is through entities where he holds voting and investment power: Ault Lending, LLC (a wholly-owned subsidiary of Hyperscale Data, Inc., where Mr. Ault is Executive Chairman), Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC.

Stakeholder Impact

• Shareholders may interpret the insider selling as a bearish signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential investors might view this as a red flag, prompting further due diligence before investing.

Key Dates

Recommendation

The significant insider selling by a Director and 10% Owner, Milton C. Ault III, signals a potential lack of confidence in Alzamend Neuro's near-term prospects or a belief that the stock is currently overvalued. Such a move by a key insider often precedes periods of underperformance or negative news, making a 'sell' recommendation prudent for investors to mitigate potential downside risk.

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Insider Selling, Form 4, Director, 10% Owner, Stock Sale, Beneficial Ownership